Combination therapy of hydroxycarbamide with anagrelide in patients
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid® efficacy and long-term safety study by Luigi Gugliotta, Carlos Besses, Martin Griesshammer, Claire Harrison, Jean. Jacques Kiladjian, Ruth Coll, Jonathan Smith, Brihad Abhyankar, and Gunnar Birgegård haematol Volume 99(4): 679 -687 March 31, 2014 © 2014 by Ferrata Storti Foundation
Summary of patient characteristics prior to starting combination therapy. Luigi Gugliotta et al. Haematologica 2014; 99: 679 -687 © 2014 by Ferrata Storti Foundation
Number of patients receiving HC + anagrelide by country enrolled. Luigi Gugliotta et al. Haematologica 2014; 99: 679 -687 © 2014 by Ferrata Storti Foundation
Summary of platelet count (× 109/L) for patients on HC + anagrelide combination therapy, prior to and during therapy. Luigi Gugliotta et al. Haematologica 2014; 99: 679 -687 © 2014 by Ferrata Storti Foundation
Summary of platelet response rates prior to and during combination therapy for patients on HC + anagrelide. Luigi Gugliotta et al. Haematologica 2014; 99: 679 -687 © 2014 by Ferrata Storti Foundation
Summary of pre-defined events experienced by at least 1% of the overall study population or patients receiving HC + anagrelide as first combination. Luigi Gugliotta et al. Haematologica 2014; 99: 679 -687 © 2014 by Ferrata Storti Foundation
Summary of patients discontinuing HC + anagrelide combination therapy (n=158). Luigi Gugliotta et al. Haematologica 2014; 99: 679 -687 © 2014 by Ferrata Storti Foundation
- Slides: 7